智飞生物
(300122)
| 流通市值：176.93亿 | | | 总市值：299.46亿 |
| 流通股本：14.14亿 | | | 总股本：23.94亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 4,023,767,992.3 | 2,150,185,419.45 | 8,958,435,384.96 | 7,644,356,433.97 |
| 营业总成本 | 4,837,680,346.44 | 2,218,602,295.96 | 12,358,235,775.89 | 8,826,798,368.98 |
| 其他经营收益 | | | | |
| 营业利润 | -968,257,240.38 | -441,995,299.04 | -17,459,994,187.58 | -1,655,892,354.87 |
| 利润总额 | -984,801,203.22 | -444,905,658.67 | -17,492,662,390.75 | -1,657,117,691.54 |
| 净利润 | -820,337,587.68 | -393,703,391.88 | -14,745,264,578.46 | -1,340,955,074.7 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | -820,337,587.68 | -393,703,391.88 | -14,745,264,578.46 | -1,340,955,074.7 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 15,071,344,831.26 | 16,417,783,333.42 | 19,019,102,113 | 36,113,056,421.78 |
| 非流动资产: | | | | |
| 非流动资产合计 | 12,746,650,028.87 | 12,674,255,942.89 | 12,700,615,190.13 | 10,302,895,862.96 |
| 资产总计 | 27,817,994,860.13 | 29,092,039,276.31 | 31,719,717,303.13 | 46,415,952,284.74 |
| 流动负债: | | | | |
| 流动负债合计 | 5,063,902,946.72 | 5,227,544,964 | 12,403,766,355.31 | 13,004,471,297.45 |
| 非流动负债: | | | | |
| 非流动负债合计 | 7,468,296,942.12 | 8,152,065,145.21 | 3,209,818,388.85 | 3,901,038,924.56 |
| 负债合计 | 12,532,199,888.84 | 13,379,610,109.21 | 15,613,584,744.16 | 16,905,510,222.01 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 15,031,270,715.08 | 15,451,462,539.53 | 15,839,778,818.53 | 29,235,038,558.13 |
| 股东权益合计 | 15,285,794,971.29 | 15,712,429,167.1 | 16,106,132,558.97 | 29,510,442,062.73 |
| 负债和股东权益合计 | 27,817,994,860.13 | 29,092,039,276.31 | 31,719,717,303.13 | 46,415,952,284.74 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 5,010,816,845.23 | 2,158,084,818.6 | 15,029,525,457.95 | 11,125,790,912.4 |
| 经营活动现金流出小计 | 3,036,473,692.78 | 1,880,015,523.79 | 9,862,205,774.26 | 8,140,772,017.83 |
| 经营活动产生的现金流量净额 | 1,974,343,152.45 | 278,069,294.81 | 5,167,319,683.69 | 2,985,018,894.57 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 24,930 | 20,000 | 89,245,175.82 | 87,773,459.91 |
| 投资活动现金流出小计 | 216,447,100.51 | 102,111,213.21 | 684,186,865.2 | 527,338,343.65 |
| 投资活动产生的现金流量净额 | -216,422,170.51 | -102,091,213.21 | -594,941,689.38 | -439,564,883.74 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 8,079,422,465.48 | 7,985,717,176 | 13,353,450,918.54 | 13,003,450,918.54 |
| 筹资活动现金流出小计 | 10,475,632,013.92 | 9,060,967,876.28 | 18,086,250,936.73 | 15,757,747,983.52 |
| 筹资活动产生的现金流量净额 | -2,396,209,548.44 | -1,075,250,700.28 | -4,732,800,018.19 | -2,754,297,064.98 |
| 汇率变动对现金及现金等价物的影响 | -475,442.49 | -16,911,711.49 | -687,237.77 | -407,575.19 |
| 现金及现金等价物净增加额 | -638,764,008.99 | -916,184,330.17 | -161,109,261.65 | -209,250,629.34 |
| 期末现金及现金等价物余额 | 1,904,196,096.32 | 1,626,775,775.14 | 2,542,960,105.31 | 2,494,818,737.62 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -638,764,008.99 | - | -161,109,261.65 | - |